Have something to share? Send us a text! Episode 27: Hormone Therapy After Breast Cancer: What Does the Evidence Say? In Episode 27 of the MenopauseWize Podcast, Dr. Sukhpreet Patel is joined by Dr. Corinne Menn, a board-certified OB-GYN, Menopause Society Certified Practitioner, and a 24-year breast cancer survivor, to explore one of the most complex and emotionally charged topics in menopause care: hormone therapy after breast cancer. For many women, surviving breast cancer is only part of the journey. The very treatments that save lives can abruptly trigger menopause — often with severe hot flashes, sleep disruption, anxiety, sexual pain, vaginal dryness, and profound changes in quality of life. Yet when it comes to hormone therapy, the conversation often ends quickly with a simple and definitive “no.” But is the evidence truly that black and white? In this thoughtful and evidence-based discussion, Dr. Menn helps us unpack: • The difference between ER-positive and ER-negative breast cancer • Why estrogen is intentionally lowered or blocked in certain cancers • How chemotherapy, ovarian suppression, tamoxifen, and aromatase inhibitors induce menopause • The difference between tamoxifen and aromatase inhibitors — and why it matters • The real-world impact of abrupt, treatment-induced menopause • The history behind avoiding systemic hormone therapy • The HABITS and Stockholm trials — what they showed and why their results differed • Whether the safety discussion differs for women on tamoxifen versus aromatase inhibitors • The severity of Genitourinary Syndrome of Menopause in breast cancer survivors • What the evidence says about low-dose vaginal estrogen after breast cancer • How to approach nuanced, individualized risk–benefit discussions Dr. Menn brings both clinical expertise and lived experience to this conversation as a breast cancer survivor and BRCA carrier. Through her telehealth practice and educational platform, she focuses on menopause management and the unique healthcare needs of female cancer survivors and women at high risk for breast cancer. This episode reinforces an essential message: the answer is not simplistic. It depends on receptor status, type of endocrine therapy, timing, symptom severity, and individual risk. Most importantly, it requires informed, shared decision-making. Breast cancer survivors deserve not only longevity — they deserve quality of life. You can follow Dr. Corinne Menn on Instagram at @drmennobgyn, where she shares thoughtful, evidence-based insights on menopause and survivorship care. As always, this episode is for educational purposes only and does not constitute individual medical advice. Please consult your healthcare team for personalized guidance. Join us for this important and nuanced conversation. Support the show The information provided in all episodes of the MenopauseWize podcast, including content shared by Sukhpreet Patel or any guest or representative, is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare consultation, diagnosis, or treatment. Always consult your physician or qualified healthcare provider regarding any medical condition or treatment decisions. SheRise Healthcare Pvt. Ltd., MenopauseWize, Sukhpreet Patel, or any representative will not be held responsible or liable for any direct, indirect, incidental, or consequential damages arising from the use or reliance on the information provided in this podcast. Listeners are encouraged to use the information at their own discretion and always seek advice from a licensed medical professional before making any healthcare decisions.
